Edition:
United Kingdom

G1 Therapeutics Inc (GTHX.OQ)

GTHX.OQ on NASDAQ Stock Exchange Global Select Market

49.11USD
9:00pm BST
Change (% chg)

$1.20 (+2.50%)
Prev Close
$47.91
Open
$48.27
Day's High
$49.67
Day's Low
$47.68
Volume
107,459
Avg. Vol
98,369
52-wk High
$52.76
52-wk Low
$12.04

Chart for

About

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38... (more)

Overall

Beta: --
Market Cap(Mil.): $731.75
Shares Outstanding(Mil.): 28.29
Dividend: --
Yield (%): --

Financials

  GTHX.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -1.88 -- --
ROI: -- 2.00 14.38
ROE: -- 3.49 16.08

BRIEF-G1 Therapeutics Reports Qtrly Loss Per Share Of $0.70

* G1 THERAPEUTICS PROVIDES FIRST QUARTER 2018 CORPORATE AND FINANCIAL UPDATE

03 May 2018

BRIEF-G1 Therapeutics Files For Offering Of 3 Mln Shares

* FILES FOR OFFERING OF 3 MILLION SHARES OF ITS COMMON STOCK Source text: (http://bit.ly/2D2beLO) Further company coverage:

05 Mar 2018

BRIEF-G1 Therapeutics Announces Positive Trilaciclib Phase 2A Topline Data Showing Robust Myelopreservation Benefits In Patients With Small Cell Lung Cancer

* G1 THERAPEUTICS ANNOUNCES POSITIVE TRILACICLIB PHASE 2A TOPLINE DATA SHOWING ROBUST MYELOPRESERVATION BENEFITS IN PATIENTS WITH SMALL CELL LUNG CANCER

05 Mar 2018

BRIEF-G1 Therapeutics Qtrly Net Loss Per Share $0.60

* G1 THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS

21 Feb 2018

Earnings vs. Estimates